For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? D ...

For those looking to find strong Retail-Wholesale stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Bed Bath & Beyond (BBBY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Retail-Wholesale peers, we might be able to answer that question.Bed Bath & Beyond is one of 200 companies in the Retail-Wholesale group. The Retail-Wholesale group currently sits at #7 within the Zacks Sector Rank. The Zack ...

Key Takeaways National Vision shares have soared 166.5% in a year, far outpacing industry and S&P 500 performance. EYE's transformation includes refreshed branding, leadership changes, and strategic partnerships. Owned & Host segment growth is boosted by new store openings and over 1M remote exams conducted. National Vision (EYE) has witnessed strong momentum over the past year. Shares of the company have risen 166.5%, outperforming the industry’s 13.3% decline during the same time frame. The S&P 500 compos ...

Key Takeaways Exxon Mobil's Guyana reserves hold nearly 11B barrels, the largest industry find in 15 years.The fourth project, Yellowtail, lifts Guyana's installed capacity beyond 900,000 barrels daily.New projects Uaru, Whiptail, and Hammerhead highlight XOM's long-term Guyana growth plans.Exxon Mobil Corporation (XOM) , a U.S.-based integrated energy firm, has a strong presence offshore Guyana, particularly in the Stabroek Block. The company stated that its Guyana reserves are one of its most advantaged a ...

Key Takeaways FN's Q4 FY25 non-optical revenues were up 41% YoY, driven by gains in automotive & industrial laser segments.FN's diversification includes medical and metrology, expanding exposure to less cyclical growth marketsZacks estimates FN's Q1 FY26 non-optical revenues to grow 29.8% YoY to $231M, reflecting continued momentum.Fabrinet's (FN) strategic push into manufacturing markets beyond optical communications is yielding substantial results, with the company's automotive and industrial laser segmen ...

Company Overview - Atara Biotherapeutics (ATRA) shares increased by 10% to close at $14.26, with notable trading volume compared to typical sessions, and a 2.6% gain over the past four weeks [1][2] Product Development - The rise in stock price is linked to growing investor optimism regarding Atara's lead product candidate, tabelecleucel (tab-cel), a T-cell immunotherapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) [2] - Atara has resubmitted its biologics license application for tab-cel, which is currently under priority review by the FDA, with a decision expected on January 10, 2026 [2] Financial Performance - Atara is projected to report a quarterly loss of $0.83 per share, reflecting a year-over-year increase of 71.7%, while revenues are expected to be $1.29 million, down 96.8% from the same quarter last year [3] - The consensus EPS estimate for Atara has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Atara Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry, which includes Amicus Therapeutics (FOLD), another stock in the same sector that closed 2.3% higher at $8.35 and has returned 8.5% over the past month [5] - Amicus Therapeutics has a consensus EPS estimate of $0.12 for its upcoming report, representing a year-over-year change of 20%, and also holds a Zacks Rank of 3 (Hold) [6]

Key Takeaways Activist play: Engine Capital urges board changes, leaner ops, and buybacks.Deep discount: ACHC trades at 8.87X forward P/E, far below peers.Risks remain: Regulatory probes and past missteps still weigh on the stock.Acadia Healthcare Company, Inc. (ACHC) shares surged 11.7% yesterday after activist investor Engine Capital revealed a 3% stake and laid out an aggressive playbook for change. From pushing for new board members and calling for asset sales to fund buybacks, to questioning the “growt ...

Nurix Therapeutics, Inc. (NRIX) shares soared 5.6% in the last trading session to close at $8.7. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.5% loss over the past four weeks.The surge in share price is likely due to positive investor expectations regarding Nurix’s set of pipeline candidates and ongoing collaboration deals with established pharma players. The company is focused on developing targeted protein degradation the ...

CarMax (KMX) reported $6.59 billion in revenue for the quarter ended August 2025, representing a year-over-year decline of 6%. EPS of $0.64 for the same period compares to $0.85 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $7.05 billion, representing a surprise of -6.52%. The company delivered an EPS surprise of -37.86%, with the consensus EPS estimate being $1.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expec ...